Healthcare
Zimmer Biomet Holdings, Inc.(ZBH)
Live Price
Offline$88.57
+1.64% today
1Y Change
-4.56%
Window
Jun 23, 2025 โ Jun 5, 2026
- Market Cap
- $16.00B
- Revenue Growth
- +7.2%
- EPS Growth
- -20.0%
- Dividend Yield
- 1.2%
Coverage: 240 bars ยท Jun 23, 2025 โ Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zimmer Biomet Holdings, Inc. (ZBH) is a Healthcare stock with a market cap of $16.00B and listed on NYSE. The stock last traded around $88.57 and down 4.6% across the available one-year price window (Jun 23, 2025 โ Jun 5, 2026). Baseline metrics include revenue growth of +7.2%, EPS growth of -20.0%, a dividend yield of 1.2%. What stands out right now is revenue +7.2%, EPS -20.0%, free cash flow +28.9% with operating margin 15.6% and ROIC 5.0%. The dividend is present but secondary, with a yield around 1.2%. Valuation is more restrained than many high-expectation growth names at P/E 21.2 and price/sales 1.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZBH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.2% vs +7.6% peer median
Operating Margin
Below sector median
+15.6% vs +19.4% peer median
P/E
Below sector median
21.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +7.2% and EPS is at -20.0%, with operating margin around 15.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | +0.4% | -3.7% | +1.3% |
2026 Feb 10, 2026 | +1.7% | +4.6% | +7.5% | +2.5% |
2025 Nov 5, 2025 | +1.6% | +1.1% | +2.8% | +6.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZBH
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZBH Max Drawdown
-26.12%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZBH and SPY.
Company Overview
Zimmer Biomet Holdings, Inc.
New York Stock Exchange
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
- Leadership
- Ivan Tornos
- IPO Date
- Jul 25, 2001
- Employees
- 17.0k
- Street Address
- 345 East Main Street
- Mailing
- Warsaw, IN, 46580
- Region
- Warsaw, IN, US
- Reporting Currency
- USD
- Investor Line
- 574 267 6131
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 21.2
- EV/EBITDA
- 10.4
- Price/Sales
- 1.9
- Price/Book
- 1.1
Growth
- Revenue
- +7.2%
- EPS
- -20.0%
- Free Cash Flow
- +28.9%
Profitability
- Gross Margin
- 70.0%
- Operating Margin
- 15.6%
- Net Margin
- 9.1%
- ROE
- 5.8%
- ROIC
- 5.0%
Balance Sheet
- Debt/Equity
- 0.51
- Current Ratio
- 2.94
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.